Valuation: Jade Biosciences, Inc.

Market Cap 1.18B 1.03B 960M 881M 1.66B 114B 1.69B 11.42B 4.47B 55.6B 4.42B 4.33B 192B P/E 2026 *
-7.63x
P/E 2027 * -7.7x
Enterprise Value 925M 811M 753M 692M 1.3B 89.29B 1.32B 8.96B 3.5B 43.64B 3.47B 3.4B 151B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.17%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jade Biosciences, Inc.

1 day-3.31%
1 week-6.98%
Current month-10.67%
1 month+18.01%
3 months-13.73%
6 months+24.53%
Current year+28.65%
1 week 19.26
Extreme 19.255
22.34
1 month 19
Extreme 19
23.49
Current year 12.45
Extreme 12.45
28
1 year 6.67
Extreme 6.67
28
3 years 6.56
Extreme 6.565
28
5 years 6.56
Extreme 6.565
28
10 years 6.56
Extreme 6.565
28
Manager TitleAgeSince
Chief Executive Officer 50 2025-04-27
Director of Finance/CFO 38 2025-07-13
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 50 2025-04-27
Director/Board Member 42 2025-04-27
Chairman 57 2025-04-27
Date Insider Type Main position Quantity % Market Cap.
6/25/26 Free

Director

47,675 0.0966%
6/9/26
Fairmount Funds Management LLC
FreeCompany 34,843 0.0706%
6/9/26 Free

Director

34,843 0.0706%
Change 5-day change 1-year change 3-year change Capi.($)
-3.31%-6.98%+128.42% - 1.22B
-4.89%-7.90%-4.49%+9.27% 48.5B
-0.14%-1.05%+376.39%+583.71% 38.97B
+0.39%+4.36%+9.59%+61.99% 35.43B
-1.54%-4.48%+24.89%-13.03% 33.65B
-0.87%-1.56%-1.43%+29.16% 26.58B
-1.28%-5.14% - - 16.82B
-0.67%-1.50%+70.98%+115.31% 15.18B
+1.32%+2.29%+14.62%+15.52% 13.89B
+0.40%-0.41%+19.80%-31.98% 12.76B
Average +0.81%-1.47%+70.97%+96.24% 24.3B
Weighted average by Cap. -0.13%-1.29%+76.39%+121.29%

Financials

2026 *2027 *
Net sales - -
Net income -173M -152M -141M -130M -244M -16.72B -248M -1.68B -656M -8.17B -650M -636M -28.25B -191M -168M -156M -143M -269M -18.46B -274M -1.85B -724M -9.02B -718M -702M -31.18B
Net Debt -254M -222M -207M -190M -357M -24.48B -363M -2.46B -961M -11.96B -952M -931M -41.35B -300M -263M -245M -225M -423M -28.99B -430M -2.91B -1.14B -14.17B -1.13B -1.1B -48.97B
Logo Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Employees
55
Date Price Change Volume
26-07-22 US$19.85 -3.31% 782,826
26-07-21 US$20.53 +4.37% 910,234
26-07-20 US$19.67 -5.70% 626,415
26-07-17 US$20.86 +1.86% 659,521
26-07-16 US$20.48 -6.31% 1,285,003
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
19.85USD
Average target price
48.50USD
Spread / Average Target
+144.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JBIO Stock